APAC Healthcare Weekly (Oct 11) – Shionogi, Terumo, Ono Pharma, Celltrion, Hanmi Pharm, CSL
Shionogi is acquiring IntraBio for $2B. Ono stuck inlicensing deal with Biohaven. Hanmi’s obesity drug got approval in Korea. CSL terminates supply...
89 Views
Ono Pharma (4528 JP): Domestic Remain Dull, Overseas Hold, Guidance Reiterated, Approvals Awaited
Ono Pharma reported 9% YoY revenue decrease in Q1FY27, with Opdivo down. Eventual indication expansions, approvals, new line of drugs may provide...
98 Views
Primer: Ono Pharmaceutical (4528 JP) - Aug 2026
Ono's financial performance is under significant pressure due to the continued sales decline of its flagship immuno-oncology drug, Opdivo, which...
100 Views
Primer: Ono Pharmaceutical (4528 JT) - Aug 2026
Ono Pharmaceutical's growth is fundamentally tied to its cornerstone immuno-oncology drug, Opdivo (nivolumab), which it co-develops with Bristol...
114 Views
Curator's Cut: Soft Commodities' Hard Truths, Pricing China's Hi-Tech & Sumitomo Pharma's Placement
This Curator's Cut highlights supply-side risks in agri-commodities, China hard-tech IPOs, and Sumitomo Pharma's share placement. Share your topic...
345 Views